Renalytix PLC
LSE:RENX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
7.5
50.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one RENX stock under the Base Case scenario is 14.35 GBX. Compared to the current market price of 7.75 GBX, Renalytix PLC is Undervalued by 46%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Renalytix PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for RENX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Renalytix PLC
Balance Sheet Decomposition
Renalytix PLC
Current Assets | 28.3m |
Cash & Short-Term Investments | 26.3m |
Receivables | 776k |
Other Current Assets | 1.3m |
Non-Current Assets | 13.8m |
PP&E | 1.2m |
Intangibles | 12.5m |
Other Non-Current Assets | 51k |
Current Liabilities | 16.1m |
Accounts Payable | 2.9m |
Accrued Liabilities | 8.6m |
Other Current Liabilities | 4.6m |
Non-Current Liabilities | 7.5m |
Long-Term Debt | 7.5m |
Earnings Waterfall
Renalytix PLC
Revenue
|
3.4m
USD
|
Cost of Revenue
|
-2.7m
USD
|
Gross Profit
|
701k
USD
|
Operating Expenses
|
-43.1m
USD
|
Operating Income
|
-42.4m
USD
|
Other Expenses
|
-3.9m
USD
|
Net Income
|
-46.2m
USD
|
Free Cash Flow Analysis
Renalytix PLC
USD | |
Free Cash Flow | USD |
In Q3 fiscal 2024, Renalytix reported revenues of $535,000, down from $724,000 a year prior, with 806 tests processed. Notably, the company has diversified its testing locations, reducing dependency on Mount Sinai. Operating expenses decreased by 40% to $6.5 million, leading to a net loss of $7.7 million, improving from $12.1 million last year. Following the FDA approval of KidneyIntelX, the sales force achieved a 33% increase in test orders. Looking ahead, they expect to onboard the FDA-authorized version broadly in 2024, with pricing set at $950 per test.
What is Earnings Call?
RENX Profitability Score
Profitability Due Diligence
Renalytix PLC's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Renalytix PLC's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
RENX Solvency Score
Solvency Due Diligence
Renalytix PLC's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Renalytix PLC's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RENX Price Targets Summary
Renalytix PLC
Dividends
Current shareholder yield for RENX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
Contact
IPO
Employees
Officers
The intrinsic value of one RENX stock under the Base Case scenario is 14.35 GBX.
Compared to the current market price of 7.75 GBX, Renalytix PLC is Undervalued by 46%.